Every article, report, and earnings note where AXSM appears.
Axsome has evolved into a commercial CNS platform with rapid revenue growth, led by Auvelity and a newly expanded Alzheimer’s agitation opportunity. The stock still earns only a Hold as losses, leverage, and a rich valuation limit upside.
A seven-stock biotech countdown spans rare-disease developers, CNS specialists, platform collaborations and commercial-stage therapeutic franchises.
Axsome Therapeutics, Inc. (AXSM) climbs after an FDA approval expanded AUVELITY into Alzheimer’s disease agitation, while Q1 2026 revenue jumped 57% year over year. Heavy volume, new highs, and higher analyst targets underscore the market’s growing confidence in Axsome’s commercial momentum.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate AXSM ReportCancel anytime